Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs

Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and mainta

NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acu

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Tra

NEWTON, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a cli

ADAR1 Capital Management LLC acquired a new position in shares of Acumen Pharmaceuticals, Inc. (NASD

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript

Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026

NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acume

NEWTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acume

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their s

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, wh

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their s

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared t

NEWTON, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company dev

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen

JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicate

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty bio

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option u

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under

Acumen Pharmaceuticals is a clinical-stage Alzheimer's biotech built around sabirnetug. I believe 20

Acumen Pharmaceuticals, Inc. (ABOS) Presents at Bank of America Global Healthcare Conference 2026 Tr

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the a

ACUMEN PHARMACEUTICALS, INC.Up to 10,833,331 shares of Common Stock    This prospectus relates to th

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and mainta

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the a

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing no

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy

Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the